Drug Profile
Liraglutide - HEC Pharm
Alternative Names: RD 12014Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Insulins; Obesity therapies; Pancreatic hormones
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Diabetes-mellitus in China (SC, Injection)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Diabetes-mellitus in China (Parenteral)
- 27 Nov 2020 HEC Pharma in collaboration with Sunshine Lake Pharma completes a phase I trial in Diabetes mellitus (SC, Injection) in China (NCT05294536)